Gornitzky represented Piper Jaffray in Vascular Biogenics Ltd.’s (operating as VBL Therapeutics) USD 18.75 million follow-on offering on the NASDAQ Global Market. VBL Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer.
Piper Jaffray & Co. acted as the sole manager for the offering.
The underwriters were represented by Chaim Friedland (Partner) and Ari Fried (Partner).
